Multiple Myeloma — RepurpOS | OpenSourceMedicine

Disease overview

Alterations

155

Molecular (A)

100

Clinical (B–E)

Direct drugs

554

Via biomarker

212

Natural agents

Natural products

Merged ranked

764

With trial/literature evidence

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed Literature, Examine.com, disease_db_100 · Pipeline phase 7 · Updated 2026-07-06

Remission & chronicity

Spontaneous remission

Essentially zero; MGUS (precursor) progresses to myeloma in 1%/year; median survival without treatment <1 year once symptomatic

Best-intervention remission

Daratumumab + VRd (daratumumab + bortezomib + lenalidomide + dexamethasone) induction + autologous SCT: 66% MRD-negative at 24 months (PERSEUS); CAR-T (idecabtagene vicleucel, ciltacabtagene autoleucel): 71-75% overall response, 28-33% CR in heavily pretreated patients; 5-year survival now ~55% (vs ~20% in 2000)

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Moderate — outcomes dramatically improved but cure remains elusive; CAR-T access critical unmet need

Primary barrier

access + biological

Barrier detail: BCMA-targeted CAR-T therapy is transformative but manufacturing delays (6+ weeks), $420K+ cost, and limited centre access restrict use; bispecific antibodies (teclistamab) offer alternative; a functional cure remains an aspiration not a reality for most patients

Last SoC change: 2024 — talquetamab (GPRC5D bispecific) approved; 2022 ciltacabtagene autoleucel CAR-T approved; 2021 idecabtagene vicleucel CAR-T first-ever for MM; 2019 daratumumab as frontline; bortezomib/lenalidomide backbone since 2003-2006

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0009693

Right to Try Relevance Critical

Eligibility: This disease meets the federal and state right-to-try legal standard (21 U.S.C. § 360bbb-0a and Montana SB 535): it lacks disease-modifying therapy with indication-specific FDA approval. Patients with Multiple Myeloma may be eligible to access investigational therapies outside of clinical trials under right-to-try frameworks.

Investigational Agents

Phase 3: 40

Most Advanced Phase

Phase 3

Highest dev. stage

Gene Targets

155

Actionable

Pipeline Compounds (Top 6)

(R)-Melphalan, Alnuctamab, Amifostine, Anitocabtagene Autoleucel, Arlocabtagene Autoleucel, Armodafinil

Legal Standard: Right-to-try requires the disease lacks "adequate approved therapy for that specific disease" (not symptom-management drugs). This distinction means a disease with antidepressants available still qualifies if no FDA approval exists for THAT disease indication.

View Right-to-Try Compendium

Alterations

Showing 80 of 155 · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
Abnormality of the bladder	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Abnormality of vitamin B12 metabolism	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Acute kidney injury	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Amyloid deposition	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Anemia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Bone pain	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Constrictive median neuropathy	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Decreased circulating immunoglobulin concentration	Lab / Clinical	Lab value	—	—	Moderate	HPO, Monarch	HPO
Elevated circulating creatinine concentration	Lab / Clinical	Lab value	—	—	Moderate	HPO, Monarch	HPO LOINC
Fatigue	Functional	Functional test	—	—	Moderate	HPO, Monarch	HPO
Functional abnormality of the gastrointestinal tract	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Generalized muscle weakness	Functional	Functional test	—	—	Moderate	HPO, Monarch	HPO
Hypercalcemia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hyperproteinemia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Increased circulating IgA concentration	Lab / Clinical	Lab value	—	—	Moderate	HPO, Monarch	HPO
Increased circulating IgG concentration	Lab / Clinical	Lab value	—	—	Moderate	HPO, Monarch	HPO
Kyphosis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Lymphadenopathy	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Multiple myeloma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Nephropathy	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Nephrotic syndrome	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Osteolysis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Osteopenia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pallor	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Paraproteinemia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Paresthesia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pathologic fracture	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Peripheral neuropathy	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pleural effusion	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Spinal cord compression	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Splenomegaly	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Tall stature	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Vertebral compression fracture	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Weight loss	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
ADRM1 ADRM1 26S proteasome ubiquitin receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AUC(0-infinity) of Cysteine-maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF) Following IV Dose of GSK2857916 in Participants With RRMM	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
AUC(0-infinity) of GSK2857916 Total Antibody Following IV Dose in Participants With RRMM	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
BCL2 BCL2 apoptosis regulator	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BRAF B-Raf proto-oncogene, serine/threonine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Best Overall Response (BOR)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
CCND1 cyclin D1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD38 CD38 molecule	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD3D CD3 delta subunit of T-cell receptor complex	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD3E CD3 epsilon subunit of T-cell receptor complex	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD3G CD3 gamma subunit of T-cell receptor complex	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDKN2A cyclin dependent kinase inhibitor 2A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CRBN cereblon	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CSF3R colony stimulating factor 3 receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CUL4A cullin 4A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CXCR4 C-X-C motif chemokine receptor 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CYLD CYLD lysine 63 deubiquitinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Change in cognitive and mental health	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Clinical Benefit Rate (CBR) by Investigator Assessment (Full Analysis Population)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Clinical Benefit Rate by Independent Review Committee (Full Analysis Population)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Complete Response Rate (CRR)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
DDB1 damage specific DNA binding protein 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Duration of Response (DOR)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Duration of Response (DoR) by Investigator Assessment (Full Analysis Population)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Duration of Response by Independent Review Committee (Full Analysis Population)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
FDPS farnesyl diphosphate synthase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FGFR3 fibroblast growth factor receptor 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GPRC5D G protein-coupled receptor class C group 5 member D	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GSR glutathione-disulfide reductase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HDAC1 histone deacetylase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HDAC10 histone deacetylase 10	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HDAC11 histone deacetylase 11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HDAC2 histone deacetylase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HDAC3 histone deacetylase 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HDAC4 histone deacetylase 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HDAC5 histone deacetylase 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HDAC6 histone deacetylase 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HDAC7 histone deacetylase 7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HDAC8 histone deacetylase 8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HDAC9 histone deacetylase 9	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IFNAR1 interferon alpha and beta receptor subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IFNAR2 interferon alpha and beta receptor subunit 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IRF4 interferon regulatory factor 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KRAS KRas proto-oncogene, GTPase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
LIG4 DNA ligase 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MAX MYC associated transcriptional regulator X	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets

FDA-Approved Therapies

Phase 4 agents with regulatory approval for this indication

Drug Name	Mechanism	Type
4-PHENYLBUTYRIC ACID		Gene-targeted
ABEMACICLIB		Gene-targeted
ACETAMINOPHEN		Gene-targeted
ACETAZOLAMIDE	None	Gene-targeted
AFATINIB		Gene-targeted
ALECTINIB		Gene-targeted
ALPELISIB		Gene-targeted
AMPHETAMINE	None	Gene-targeted
ARSENIC TRIOXIDE		Gene-targeted
ATEZOLIZUMAB		Gene-targeted
AXITINIB		Gene-targeted
BEVACIZUMAB		Gene-targeted
BICALUTAMIDE	None	Gene-targeted
BINIMETINIB		Gene-targeted
BLINATUMOMAB	antibody	Gene-targeted
BLINATUMOMAB	modulator	Gene-targeted
BORTEZOMIB	inhibitor	Gene-targeted
BORTEZOMIB D-MANNITOL	inhibitor	Gene-targeted
BOSUTINIB		Gene-targeted
BRENTUXIMAB VEDOTIN		Gene-targeted
CAPECITABINE		Gene-targeted
CAPMATINIB		Gene-targeted
CARBACHOL	None	Gene-targeted
CARBOPLATIN		Gene-targeted
CARFILZOMIB	inhibitor	Gene-targeted
CATUMAXOMAB	modulator	Gene-targeted
CELECOXIB		Gene-targeted
CETUXIMAB		Gene-targeted
CHLOROQUINE		Gene-targeted
CIPROFLOXACIN	None	Gene-targeted
CISPLATIN		Gene-targeted
CLOMIPRAMINE	None	Gene-targeted
COBIMETINIB		Gene-targeted
CRIZOTINIB		Gene-targeted
CYTARABINE		Gene-targeted
DABRAFENIB	inhibitor; inhibitor	Gene-targeted
DABRAFENIB MESYLATE	inhibitor	Gene-targeted
DARATUMUMAB	inhibitor; antibody	Gene-targeted
DASATINIB ANHYDROUS	inhibitor	Gene-targeted
DENOSUMAB		Gene-targeted

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, and merged ranking. Only agents with registry trials or published clinical literature are shown by default.

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
SIROLIMUS	Small molecule	Approved	Strong	100	8 trials View evidence Registry trials NCT01396200 — Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine (COMPLETED) EARLY_PHASE1 NCT00060645 — Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED) (COMPLETED) PHASE1 NCT01244906 — Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant (COMPLETED) PHASE2 NCT00589563 — Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer (COMPLETED) PHASE2 NCT00105001 — Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer (COMPLETED) PHASE2 NCT00918333 — Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma (COMPLETED) PHASE1, PHASE2 NCT00544115 — Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders (ACTIVE_NOT_RECRUITING) PHASE2 NCT01231412 — Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant (COMPLETED) PHASE3 CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
TACROLIMUS ANHYDROUS	Small molecule	Approved	Strong	100	8 trials View evidence Registry trials NCT00143845 — Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant (COMPLETED) PHASE2 NCT01518153 — Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT) (TERMINATED) PHASE2 NCT01875237 — Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene (TERMINATED) PHASE1, PHASE2 NCT02566304 — Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies (COMPLETED) PHASE2 NCT00423826 — Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease (NO_LONGER_AVAILABLE) NCT00004145 — Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer (COMPLETED) PHASE2 NCT00281879 — Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer (TERMINATED) PHASE2 NCT00448201 — Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
4-PHENYLBUTYRIC ACID Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ABEMACICLIB Repurposing	Small molecule	Approved	Strong	95	3 trials View evidence Registry trials NCT03732703 — Myeloma-Developing Regimens Using Genomics (MyDRUG) (COMPLETED) PHASE1, PHASE2 NCT02693535 — TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (RECRUITING) PHASE2 NCT03878524 — Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (TERMINATED) PHASE1 CT.gov search · Cochrane · PubMed	DGIdb	—
ACETAMINOPHEN Repurposing	Small molecule	Approved	Strong	95	8 trials View evidence Registry trials NCT07101445 — Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial (RECRUITING) PHASE4 NCT04270409 — Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma (ACTIVE_NOT_RECRUITING) PHASE3 NCT05298683 — A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor (UNKNOWN) PHASE2 NCT01846429 — Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain (TERMINATED) PHASE1 NCT04268498 — A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma (ACTIVE_NOT_RECRUITING) PHASE2 NCT00176475 — Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease (TERMINATED) PHASE1 NCT02661035 — Allo HSCT Using RIC for Hematological Diseases (COMPLETED) PHASE2 NCT02541643 — Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma (NO_LONGER_AVAILABLE) CT.gov search · Cochrane · PubMed	DGIdb	—
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
AFATINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ALECTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ALPELISIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ARSENIC TRIOXIDE Repurposing	Small molecule	Approved	Strong	95	8 trials View evidence Registry trials NCT00085345 — Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma (WITHDRAWN) PHASE2 NCT00258245 — Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia (COMPLETED) PHASE1 NCT00112879 — Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma (WITHDRAWN) PHASE2 NCT00006021 — Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma (COMPLETED) PHASE1, PHASE2 NCT00469209 — Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients (COMPLETED) PHASE1, PHASE2 NCT00590603 — Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma (TERMINATED) PHASE1 NCT00504101 — Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma (WITHDRAWN) PHASE1 NCT00006220 — Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy (TERMINATED) PHASE1, PHASE2 CT.gov search · Cochrane · PubMed	DGIdb	—
ATEZOLIZUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AXITINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BEVACIZUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BINIMETINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BLINATUMOMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BLINATUMOMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BORTEZOMIB Repurposing	Small molecule	Approved	Strong	95	8 trials 2 Trial pubs View evidence Registry trials NCT02928029 — Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma (TERMINATED) PHASE1, PHASE2 NCT02513186 — Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation (COMPLETED) PHASE1 NCT01470131 — A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma (TERMINATED) PHASE3 NCT07671287 — GMMG-HD11/DSMM XXI/64007957MMY3010 (NOT_YET_RECRUITING) PHASE3 NCT00872352 — Evaluation of Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients (UNKNOWN) PHASE3 NCT03344328 — Prevalence, Intensity and Consequences of Bortezomib-induced Neuropathic Disorders. (COMPLETED) NCT03089411 — Collection of Additional Data Followed the Study IFM 2013-04 (UNKNOWN) NCT00536575 — Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients (COMPLETED) PHASE1, PHASE2 Published literature Clinical trial publication Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study (The Lancet. Oncology, 2018) Clinical trial publication Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: a prospective multicenter study (BioMed research international, 2014) CT.gov search · Cochrane · PubMed	DGIdb	—
BORTEZOMIB D-MANNITOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BOSUTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BRENTUXIMAB VEDOTIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPECITABINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPMATINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CARBOPLATIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CARFILZOMIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CATUMAXOMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CELECOXIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CETUXIMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CHLOROQUINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CIPROFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CISPLATIN Repurposing	Small molecule	Approved	Strong	95	8 trials View evidence Registry trials NCT00574080 — UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide (TERMINATED) PHASE3 NCT01849783 — Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma (COMPLETED) PHASE2 NCT03004287 — 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy (ACTIVE_NOT_RECRUITING) PHASE2 NCT00089453 — Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant (COMPLETED) PHASE1 NCT00869232 — UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission (ACTIVE_NOT_RECRUITING) PHASE2 NCT00577096 — Effects of Exercise in Combination With Epoetin Alfa (COMPLETED) NA NCT00580372 — UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma (COMPLETED) PHASE2 NCT01055301 — S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma (WITHDRAWN) PHASE2 CT.gov search · Cochrane · PubMed	DGIdb	—
CLOMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
COBIMETINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CRIZOTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CYTARABINE Repurposing	Small molecule	Approved	Strong	95	8 trials View evidence Registry trials NCT00574080 — UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide (TERMINATED) PHASE3 NCT00423826 — Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease (NO_LONGER_AVAILABLE) NCT00002818 — High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies (COMPLETED) PHASE1 NCT00002502 — Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome (COMPLETED) PHASE2 NCT00281879 — Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer (TERMINATED) PHASE2 NCT01653418 — Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation (TERMINATED) PHASE2 NCT00691015 — Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant (COMPLETED) PHASE2 NCT01008462 — Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	DGIdb	—
DABRAFENIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DABRAFENIB MESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DARATUMUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DASATINIB ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DENOSUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DIAZEPAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DIETHYLSTILBESTROL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DOCETAXEL ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DOXORUBICIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	8 trials View evidence Registry trials NCT00008242 — Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma (COMPLETED) PHASE2 NCT00148317 — Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma (COMPLETED) PHASE2 NCT00006184 — Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma (COMPLETED) PHASE2 NCT01849783 — Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma (COMPLETED) PHASE2 NCT03004287 — 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy (ACTIVE_NOT_RECRUITING) PHASE2 NCT00401804 — Bortezomib-Dexamethasone-Doxorubicin-Study (COMPLETED) PHASE2 NCT00135187 — Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma (COMPLETED) NA NCT00002878 — Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma (COMPLETED) PHASE3 CT.gov search · Cochrane · PubMed	DGIdb	—
DOXORUBICIN LIPOSOME Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
EDARAVONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—

Drug	Type	Phase	Evidence	Score	Sources	Links
(R)-MELPHALAN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ALNUCTAMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
AMIFOSTINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ANITOCABTAGENE AUTOLEUCEL	Gene therapy	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ARLOCABTAGENE AUTOLEUCEL	Gene therapy	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ARMODAFINIL	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
BENDAMUSTINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
BETAMETHASONE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
BETAMETHASONE DIPROPIONATE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
BETAMETHASONE SODIUM PHOSPHATE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
BUSULFAN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CEVOSTAMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CISPLATIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CLARITHROMYCIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
COLCHICINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CYTARABINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
DOCETAXEL	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
EPOETIN ALFA	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
EPOETIN BETA	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
EQUECABTAGENE AUTOLEUCEL	Gene therapy	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ETENTAMIG	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ETOPOSIDE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
FELZARTAMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
FILGRASTIM	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
FLUDARABINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
HYALURONIDASE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
IBANDRONIC ACID	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
IBERDOMIDE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
IDARUBICIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
INTERFERON ALFA	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
IRON SUCROSE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
LENOGRASTIM	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
LOMUSTINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
LORNOXICAM	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
MASITINIB	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
METHYLPREDNISOLONE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
METHYLPREDNISOLONE ACETATE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
MEZIGDOMIDE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
MOLGRAMOSTIM	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
NARLUMOSBART	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
4-PHENYLBUTYRIC ACID Repurposing via BCL2	Small molecule	Approved	Strong	95	—	DGIdb	—
ABEMACICLIB Repurposing via CCND1	Small molecule	Approved	Strong	95	3 trials View evidence Registry trials NCT03732703 — Myeloma-Developing Regimens Using Genomics (MyDRUG) (COMPLETED) PHASE1, PHASE2 NCT02693535 — TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (RECRUITING) PHASE2 NCT03878524 — Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (TERMINATED) PHASE1 CT.gov search · Cochrane · PubMed	DGIdb	—
ACETAMINOPHEN Repurposing via CCND1	Small molecule	Approved	Strong	95	8 trials View evidence Registry trials NCT07101445 — Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial (RECRUITING) PHASE4 NCT04270409 — Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma (ACTIVE_NOT_RECRUITING) PHASE3 NCT05298683 — A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor (UNKNOWN) PHASE2 NCT01846429 — Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain (TERMINATED) PHASE1 NCT04268498 — A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma (ACTIVE_NOT_RECRUITING) PHASE2 NCT00176475 — Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease (TERMINATED) PHASE1 NCT02661035 — Allo HSCT Using RIC for Hematological Diseases (COMPLETED) PHASE2 NCT02541643 — Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma (NO_LONGER_AVAILABLE) CT.gov search · Cochrane · PubMed	DGIdb	—
ACETAZOLAMIDE Repurposing via ADRM1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
AFATINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
ALECTINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
ALPELISIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
AMPHETAMINE Repurposing via ADRM1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ARSENIC TRIOXIDE Repurposing via CCND1	Small molecule	Approved	Strong	95	8 trials View evidence Registry trials NCT00085345 — Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma (WITHDRAWN) PHASE2 NCT00258245 — Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia (COMPLETED) PHASE1 NCT00112879 — Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma (WITHDRAWN) PHASE2 NCT00006021 — Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma (COMPLETED) PHASE1, PHASE2 NCT00469209 — Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients (COMPLETED) PHASE1, PHASE2 NCT00590603 — Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma (TERMINATED) PHASE1 NCT00504101 — Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma (WITHDRAWN) PHASE1 NCT00006220 — Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy (TERMINATED) PHASE1, PHASE2 CT.gov search · Cochrane · PubMed	DGIdb	—
ATEZOLIZUMAB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
AXITINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
BEVACIZUMAB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing via ADRM1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BINIMETINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
BLINATUMOMAB Repurposing via CD3D	Small molecule	Approved	Strong	95	—	DGIdb	—
BLINATUMOMAB Repurposing via CD3G	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BORTEZOMIB Repurposing via CCND1	Small molecule	Approved	Strong	95	8 trials 2 Trial pubs View evidence Registry trials NCT02928029 — Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma (TERMINATED) PHASE1, PHASE2 NCT02513186 — Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation (COMPLETED) PHASE1 NCT01470131 — A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma (TERMINATED) PHASE3 NCT07671287 — GMMG-HD11/DSMM XXI/64007957MMY3010 (NOT_YET_RECRUITING) PHASE3 NCT00872352 — Evaluation of Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients (UNKNOWN) PHASE3 NCT03344328 — Prevalence, Intensity and Consequences of Bortezomib-induced Neuropathic Disorders. (COMPLETED) NCT03089411 — Collection of Additional Data Followed the Study IFM 2013-04 (UNKNOWN) NCT00536575 — Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients (COMPLETED) PHASE1, PHASE2 Published literature Clinical trial publication Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study (The Lancet. Oncology, 2018) Clinical trial publication Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: a prospective multicenter study (BioMed research international, 2014) CT.gov search · Cochrane · PubMed	DGIdb	—
BORTEZOMIB D-MANNITOL Repurposing via ADRM1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BOSUTINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
BRENTUXIMAB VEDOTIN Repurposing via BCL2	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPECITABINE Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPMATINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing via ADRM1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CARBOPLATIN Repurposing via BCL2	Small molecule	Approved	Strong	95	—	DGIdb	—
CARFILZOMIB Repurposing via ADRM1	Small molecule	Approved	Strong	95	—	DGIdb	—
CATUMAXOMAB Repurposing via CD3D	Small molecule	Approved	Strong	95	—	DGIdb	—
CELECOXIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CETUXIMAB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CHLOROQUINE Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CIPROFLOXACIN Repurposing via ADRM1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CISPLATIN Repurposing via CCND1	Small molecule	Approved	Strong	95	8 trials View evidence Registry trials NCT00574080 — UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide (TERMINATED) PHASE3 NCT01849783 — Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma (COMPLETED) PHASE2 NCT03004287 — 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy (ACTIVE_NOT_RECRUITING) PHASE2 NCT00089453 — Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant (COMPLETED) PHASE1 NCT00869232 — UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission (ACTIVE_NOT_RECRUITING) PHASE2 NCT00577096 — Effects of Exercise in Combination With Epoetin Alfa (COMPLETED) NA NCT00580372 — UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma (COMPLETED) PHASE2 NCT01055301 — S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma (WITHDRAWN) PHASE2 CT.gov search · Cochrane · PubMed	DGIdb	—
CLOMIPRAMINE Repurposing via ADRM1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
COBIMETINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CRIZOTINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CYTARABINE Repurposing via CCND1	Small molecule	Approved	Strong	95	8 trials View evidence Registry trials NCT00574080 — UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide (TERMINATED) PHASE3 NCT00423826 — Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease (NO_LONGER_AVAILABLE) NCT00002818 — High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies (COMPLETED) PHASE1 NCT00002502 — Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome (COMPLETED) PHASE2 NCT00281879 — Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer (TERMINATED) PHASE2 NCT01653418 — Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation (TERMINATED) PHASE2 NCT00691015 — Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant (COMPLETED) PHASE2 NCT01008462 — Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	DGIdb	—
DABRAFENIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
DABRAFENIB MESYLATE Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DARATUMUMAB Repurposing via CD38	Small molecule	Approved	Strong	95	—	DGIdb	—
DASATINIB ANHYDROUS Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
DENOSUMAB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—

Natural Products

1 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked). Only agents with direct clinical evidence are shown by default.

Reference lookups: Examine.com

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
Curcumin Natural product Human Study Curcumin has potential in the treatment of plasma cell dyscrasias. Human: Case Report Administered curcumin to a patient with laryngeal amyloidosis and smold…	Food compound	Phase II	Emerging	7	6 trials View evidence Registry trials NCT04731844 — Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer (COMPLETED) PHASE2 NCT05640843 — A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) (RECRUITING) NA NCT01269203 — Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients (WITHDRAWN) PHASE2 NCT06055894 — A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS) (RECRUITING) NA NCT00113841 — Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma (COMPLETED) NA NCT07456605 — Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma (RECRUITING) PHASE1 CT.gov search · Cochrane · PubMed		PubChem

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.